Mveang Nzoghe Amandine, Leboueny Marielle, Kuissi Kamgaing Eliane, Maloupazoa Siawaya Anicet Christel, Bongho Eliode Cyrien, Mvoundza Ndjindji Ofilia, Padzys Guy-Stephan, Ndeboko Bénédicte, Ategbo Simon, Djoba Siawaya Joel Fleury
Service Laboratoire, Centre Hospitalier Universitaire (CHU) - Mère-Enfant), Fondation Jeanne EBORI, Libreville, Gabon.
Pôle enfant, Service de Néotatologie, CHU- Mère-Enfant Fondation Jeanne EBORI, Libreville, Gabon.
BMC Res Notes. 2021 Apr 20;14(1):152. doi: 10.1186/s13104-021-05570-3.
Herd immunity is achieved when in a population, immune individuals are in a sufficiently large proportion. Neutralizing antibodies specific to SARS-CoV-2 that are produced following infection or vaccination are critical for controlling the spread of COVID-19. The objective of the present work was to investigate the rate of SARS-CoV-2 natural immunization in Gabonese.
One thousand, four hundred and ninety two people were enrolled. The overall prevalence of anti-SARS-CoV-2 antibodies was 36.2%. Moreover, 76.4% of people who developed a humoral response to SARS-CoV-2 produced both anti-SARS-CoV-2 N-protein antibodies and anti-SARS-CoV-2 S-protein antibodies, which correspond to 27.7% of the total population. In infants (0-9 month), children (1-17 years) and adults, the prevalence of anti-SARS-CoV-2 antibodies was relatively the same, between 33 and 37% (any antibody types) and between 25 and 28.6% (neutralizing antibodies). In this African context, one-third (1/3) of the screened population was exposed to SARS-CoV-2 and three-quarter (3/4) of those exposed individuals developed neutralizing antibodies against SARS-CoV-2. This data suggest that herd immunity is not yet to be achieved in Gabon.
当人群中免疫个体占足够大比例时，就实现了群体免疫。感染或接种疫苗后产生的针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的中和抗体对于控制2019冠状病毒病（COVID-19）的传播至关重要。本研究的目的是调查加蓬人SARS-CoV-2自然免疫的发生率。
共纳入1492人。抗SARS-CoV-2抗体的总体流行率为36.2%。此外，对SARS-CoV-2产生体液反应的人群中，76.4%的人同时产生了抗SARS-CoV-2 N蛋白抗体和抗SARS-CoV-2 S蛋白抗体，这相当于总人口的27.7%。在婴儿（0 - 9个月）、儿童（1 - 17岁）和成年人中，抗SARS-CoV-2抗体的流行率相对相同，在33%至37%之间（任何抗体类型），在25%至28.6%之间（中和抗体）。在这种非洲背景下，三分之一（1/3）的筛查人群接触过SARS-CoV-2，四分之三（3/4）的接触者产生了针对SARS-CoV-2的中和抗体。这些数据表明加蓬尚未实现群体免疫。
